Cargando…
Evaluation and Optimization of in silico designed Sphingosine-1-Phosphate (S1P) Receptor Subtype 1 Modulators for the Management of Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the Central Nervous System (CNS) through inflammation, demyelination and neurodegeneration. Sphingosine-1-phosphate receptor (S1PR1) modulators have been approved for the management of MS. Phosphorylated fingolimod mimics endogenous...
Autores principales: | Gusman, Daphne H., Shoemake, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
YJBM
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369033/ https://www.ncbi.nlm.nih.gov/pubmed/28356890 |
Ejemplares similares
-
Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis
por: Musella, Alessandra, et al.
Publicado: (2020) -
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis
por: Dumitrescu, Laura, et al.
Publicado: (2023) -
Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis
por: Chiba, Kenji, et al.
Publicado: (2012) -
Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017) -
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)